Tagged with GENZ

Pharma Bert de Jong, General Manager Benelux at Genzyme, discusses the solutions Genzyme is offering to patients suffering from rare diseases and MS in the Benelux and how these treatments add value overall to society, as well as the company’s changing role in the Sanofi organization with the addition of the oncology and…

Genzyme Genzyme Turkey’s general manager discusses diagnosis and treatment access issues for rare diseases, the need for prioritization of patient welfare in all aspects of health policy, and the importance of the Turkish market and its potential to Genzyme globally. For rare diseases, do Turkish patients have adequate access to the…

Ireland   What makes Ireland attractive for FDI? As the former general manager of Genzyme’s Waterford site, Pat O’Sullivan explains that a longstanding 12.5% corporate tax rate (that isn’t going anywhere) is one factor, but it doesn’t end there. Talent: “The first factor is the excellence of the workforce, which is…

Genzyme - Ireland Mr. Martin, you were appointed as Genzyme’s GM for UK and Ireland last month after having spent a decade at the organization. Robin Kenselaar, Head of Genzyme EMEA, noted that your appointment came at a “key time for the business.” What is your understanding of where this company is going…

Genzyme Chile Genzyme was first established in Chile in 2004 but only opened its sales office in 2008, what was the rationale for the opening of the office at this time considering that you had been present in neighbouring countries 10 years before? The Chilean market is a very difficult one. We…

Genzyme de Colombia S.A. What is the role, significance, and importance of the Colombian market within the larger global strategy of Genzyme international? Colombia is a very important country because we have a market with a well developed, and in that way different, health system from other countries in the Andean region. Of course…

Genzyme Poland With the current acquisition of Genzyme by Sanofi-Aventis, the French giant is planning to have Genzyme as a centre of excellence for rare diseases. Genzyme operates in the genetic market, in bio-surgery, in oncology, and also in transplant. What area has been driving the growth in 2010? In value terms,…

Genzyme (Shanghai) In 2006, Genzyme’s global CEO, Henri Termeer, said he is “personally very interested in China” and that he expects the company to build a capable infrastructure in ten years. We’re now 30% closer to the deadline. How has this deep commitment to China resulted in developments in the country and…

Genzyme Australia What impact will the recent PBS reforms have on Genzyme’s operations in Australia? Genzyme is different in terms of its focus on rare & unmet medical needs, so most of the company’s products, given they are targeted therapies, are not reimbursed through the PBS, but through other government funding mechanisms.…